Literature DB >> 11688576

CD31 expression in intratumoral macrophages: a potential diagnostic pitfall.

J K McKenney1, S W Weiss, A L Folpe.   

Abstract

CD31 (platelet endothelial adhesion molecule, PECAM-1) is generally regarded to be the most sensitive and specific endothelial marker in paraffin sections. We have recently encountered several cases in which intratumoral CD31-positive macrophages were misinterpreted as evidence of a vascular sarcoma. We therefore reviewed our last 1950 consultation cases with respect to cases in which CD31 immunostains were performed, to determine the frequency of CD31 expression in macrophages in formalin-fixed, paraffin-embedded tissue and how often the presence of these cells was a source of diagnostic confusion. CD31 immunohistochemistry had been performed on 59 of 1950 (3%) of cases. These 59 cases consisted of both vascular (20 cases) and nonvascular tumors (39 cases). CD31-positive macrophages were distinguished from endothelial or tumor cells by correlation with the morphologic features and the immunohistochemical staining pattern of the cells of interest. In no case was CD31 positivity seen in the lesional cells of a nonvascular tumor. CD31-positive macrophages were identified in 48 of 59 (81%) cases. CD31-positive macrophages were present in 34 of 39 (87%) nonvascular tumors. A vascular tumor was diagnosed or favored by the referring pathologist in 15 of these 39 cases (38%). In 14 of these 15 cases CD31 immunostains were performed by the referring pathologist; 13 (93%) showed CD31-positive macrophages. In 4 of these 14 cases (29%) the misdiagnosis of a vascular tumor was based primarily or in part on the misinterpretation of CD31-positive macrophages as tumor cells. In all cases with CD34 and CD68 immunostains, the CD31-positive macrophages were CD34 negative and CD68 positive. We conclude that CD31 expression is very common in macrophages. Misinterpretation of CD31-positive macrophages as tumor cells may result in the erroneous diagnosis of a primary vascular neoplasm. Recognition of the characteristic granular, membranous pattern of CD31 expression in macrophages and careful distinction from tumor cells should allow the accurate interpretation of CD31 immunohistochemistry in possible vascular neoplasms. CD31 may also be useful as a nonlysosomal marker of macrophages in formalin-fixed, paraffin-embedded sections.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11688576     DOI: 10.1097/00000478-200109000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  31 in total

1.  Caution should be taken in using CD31 for distinguishing the vasculature of lymph nodes.

Authors:  H Hattori
Journal:  J Clin Pathol       Date:  2003-08       Impact factor: 3.411

2.  Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors.

Authors:  Markku Miettinen; Maarit-Sarlomo Rikala; Janusz Rys; Jerzy Lasota; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2012-04       Impact factor: 6.394

3.  [Pitfalls. A new rubric in Der Pathologe].

Authors:  C Kuhnen; K W Schmid
Journal:  Pathologe       Date:  2012-03       Impact factor: 1.011

4.  Claudin-5 as an immunohistochemical marker for angiosarcoma and hemangioendotheliomas.

Authors:  Markku Miettinen; Maarit Sarlomo-Rikala; Zeng-Feng Wang
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

5.  Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

Authors:  Anna R Kwilas; Renee N Donahue; Kwong Y Tsang; James W Hodge
Journal:  Cancer Cell Microenviron       Date:  2015

6.  ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma.

Authors:  Markku Miettinen; Zeng-Feng Wang; Anders Paetau; Shyh-Han Tan; Albert Dobi; Shiv Srivastava; Isabell Sesterhenn
Journal:  Am J Surg Pathol       Date:  2011-03       Impact factor: 6.394

7.  Magnetic resonance imaging and immunohistochemistry of primary vertebral hemangiosarcoma in a dog and implications for diagnosis and therapy.

Authors:  Claudia Pérez-Martínez; Marta Regueiro-Purriños; Beatriz Fernández-Martínez; José R Altónaga; José M Gonzalo-Orden; María J García-Iglesias
Journal:  Can Vet J       Date:  2016-12       Impact factor: 1.008

8.  A practical and comprehensive immunohistochemical approach to the diagnosis of superficial soft tissue tumors.

Authors:  Wael Al-Daraji; Ehab Husain; Bettena G Zelger; Bernhard Zelger
Journal:  Int J Clin Exp Pathol       Date:  2008-06-10

9.  The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.

Authors:  Dita Gratzinger; Shuchun Zhao; Robert West; Robert V Rouse; Hannes Vogel; Elena Cubedo Gil; Ronald Levy; Izidore S Lossos; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2009-02       Impact factor: 2.493

10.  Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.

Authors:  Benedetto Farsaci; Renee N Donahue; Michael A Coplin; Italia Grenga; Lauren M Lepone; Alfredo A Molinolo; James W Hodge
Journal:  Cancer Immunol Res       Date:  2014-08-04       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.